Skip to content
Westlake BioPartners
  • People
  • Portfolio
  • About
  • News
  • Contact
Westlake BioPartners
  • People
  • Portfolio
  • About
  • News
  • Contact
Back

Checking in on the progress of CAR-T for autoimmune conditions with the CEO of Kyverna – the company’s first (and first for the field) registration intended trial will read in the first half of 2026

August 13, 2025

Warner Biddle describes the trajectory of the field, and how neuro-autoimmune conditions have emerged as Kyverna's most advanced programs. We discuss Stiff Person Syndrome, myasthenia gravis, MS and more.

https://www.biotechtv.com/post/kyverna-therapeutics-august-13-2025

Previous Post
  • People
  • Portfolio
  • About
  • News
  • Contact

© 2025 Westlake BioPartners. All Rights Reserved. Privacy Policy